'Smart scaffolds' likely to heal broken hearts
New treatments are being developed that heal broken hearts or muscle loss by prompting the the body to repair damaged tissues.health and fitness Updated: Jan 14, 2009 17:33 IST
New treatments are being developed that heal broken hearts or muscle loss by prompting the the body to repair damaged tissues.
Canadian researchers, for the first time, have developed an organic substance (scaffold) that attracts and supports cells necessary for tissue repair and can be directly injected into problem areas.
This development is a major step toward treatments that allow people to more fully recover from injury and disease rather than having to live with chronic health problems.
It may even help reduce the need for organ transplantation by allowing physicians to save organs that would have been previously damaged beyond repair.
These 'smart scaffolds', developed by Erik Suuronen and his colleagues from the University of Ottawa and Ottawa Heart Research Institute, contain a protein that allows progenitor cells to adhere to the damaged tissue and survive long enough to promote healing.
These cells emit homing signals that summon other cells to join in the process and give off chemical signals that order cells to grow blood vessels necessary for healing to occur.
"Ultimately, we envision a scaffold material that can be taken off the shelf and injected into the hearts of patients suffering from blocked arteries," said Suuronen. "The scaffold materials would direct the repair process, and restore blood flow and function to the heart."
The researchers tested this material in three groups of rats, with each group suffering from a lack of blood oxygen (ischemia) to their thigh muscles. The muscles in the first group were treated with the smart scaffold.
The second group received a scaffold not engineered for cell attachment. The third group received a placebo. Two weeks after treatment, rats treated with the "smart" scaffold had more new blood vessels and better functional recovery while rats from the other two groups only had minimal improvement, said an Ottawa release.
"This is a major development toward radically new treatments for heart and muscle disease," said Gerald Weissmann, editor-in-chief of The FASEB Journal that published the study.